INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

Showing studies that examined mushrooms. Clear

10 studies

2019 / Systematic review of clinical studies

Clinical studies link mushroom-derived lentinan to benefits during conventional cancer therapy.

A systematic review evaluated 135 clinical studies from China comprising 9,474 cancer treatment cases involving the shiitake polysaccharide lentinan. Most cases involved lung (3,469), gastric (3,039), or colorectal (1,646) malignancies. Across evaluated reports, lentinan use was linked to better quality of life and greater efficacy of concurrent chemotherapy or radiation treatment.

Zhang M, Zhang Y, Zhang L, et al. Prog Mol Biol Transl Sci, 2019. PMID 31030752

2012 / Meta-analysis of randomized controlled trials

Reishi mushroom as an adjunct to cancer therapy showed potential immune and response benefits

A meta-analysis of five randomized trials examined Ganoderma lucidum in cancer care. Combining the mushroom with chemotherapy or radiotherapy increased the likelihood of a positive response compared to conventional therapy alone (RR 1.50, 95% CI 0.90 to 2.51). Furthermore, supplementation raised CD3, CD4, and CD8 percentages by 3.91%, 3.05%, and 2.02%, while quality of life was relatively improved in four studies.

Jin X, Ruiz Beguerie J, Sze DM, et al. Cochrane Database Syst Rev, 2012. PMID 22696372

2015 / Phase I trial

White button mushroom powder showed biological activity in biochemically recurrent prostate cancer.

Thirty-six patients with rising prostate-specific antigen levels received escalating doses of white button mushroom powder in a phase I trial. No dose-limiting toxicities occurred, and the overall prostate-specific antigen response rate was 11%. Complete responses occurred in two patients receiving 8 and 14 g/d, with reductions to undetectable levels lasting 49 and 30 months.

Twardowski P, Kanaya N, Frankel P, et al. Cancer, 2015. PMID 25989179

2010 / Open-label study

Neither Agaricus blazei nor Ganoderma lucidum mushroom supplements showed significant anticancer effects in prostate cancer patients with biochemical failure.

In an open-label study, 51 patients with biochemical failure following radical prostatectomy for non-metastasized prostate cancer took either Senseiro (Agaricus blazei Murill extract, n=32) or Rokkaku Reishi (Ganoderma lucidum, n=15) for 6 months. Forty-seven patients completed the protocol and were assessed. No partial response (a 50% or greater decrease in serum PSA) was observed in any patient. Alteration of PSA doubling time did not correlate with serum testosterone levels, and no serious adverse effects were observed.

Yoshimura K, Kamoto T, Ogawa O, et al. Int J Urol, 2010. PMID 20412340

2002 / Open-label clinical trial

Shiitake mushroom mycelium extract did not lower PSA levels in prostate cancer.

Sixty-two men with histologically proven prostate cancer and elevated PSA received shiitake mushroom mycelium extract capsules three times daily for 6 months. Among 61 assessable patients, zero achieved a complete or partial PSA response, 23 developed disease progression, and 38 maintained stable PSA levels. When pre-study PSA trajectories were examined, only 4 of 61 patients (7%) demonstrated stabilized disease while taking the supplement.

deVere White RW, Hackman RM, Soares SE, et al. Urology, 2002. PMID 12385925

2020 / Pooled prospective cohort study

Frequent mushroom intake was associated with a decreased risk of incident prostate cancer in Japanese men.

Researchers analyzed pooled data from 36,499 Japanese men followed for a median of 13.2 years (574,397 person-years) to examine mushroom consumption and prostate cancer risk. During follow-up, 1,204 incident prostate cancer cases (3.3%) occurred. Compared to consuming mushrooms <1 time/week, consumption 1-2 times/week was associated with an HR of 0.92 (95% CI: 0.81, 1.05) and ≥3 times/week with an HR of 0.83 (95% CI: 0.70, 0.98; p-trend = 0.023). This inverse relationship was particularly apparent in men aged ≥50 years and did not differ by clinical cancer stage or intake of vegetables, fruit, meat, and dairy products.

Shows an association, not proof of cause and effect.

Zhang S, Sugawara Y, Chen S, et al. Int J Cancer, 2020. PMID 31486077

2019 / Prospective cohort study

Mushroom consumption was not associated with the risk of total or most site-specific cancers in two large U.S. cohorts.

This prospective study followed 68,327 women and 44,664 men for up to 26 years, documenting 22,469 incident cancer cases. In pooled multivariable analysis, participants consuming five or more servings of mushrooms per week had no significantly different risk of total cancer compared to those who almost never consumed mushrooms (HR, 1.06; 95% CI, 0.98-1.14). Mushroom consumption was not associated with 16 site-specific cancers, although a marginal positive association was observed for lung cancer (P trend = 0.05).

Shows an association, not proof of cause and effect.

Lee DH, Yang M, Keum N, et al. Cancer Prev Res (Phila), 2019. PMID 31164344

2014 / Case report

Ingestion of Chaga mushroom powder was associated with oxalate nephropathy and hemodialysis in a 72-year-old female.

A 72-year-old Japanese female with liver cancer had ingested 4 - 5 teaspoons per day of Chaga mushroom powder for 6 months. Renal function decreased and hemodialysis was initiated. Renal biopsy showed diffuse tubular atrophy, interstitial fibrosis, and oxalate crystals detected in the tubular lumina and urinary sediment, resulting in a diagnosis of oxalate nephropathy. The authors noted that Chaga mushrooms contain extremely high oxalate concentrations.

Shows an association, not proof of cause and effect.

Kikuchi Y, Seta K, Ogawa Y, et al. Clin Nephrol, 2014. PMID 23149251

2009 / Case-control study

Higher dietary mushroom intake and its combination with green tea were linked to lower breast cancer risk in Chinese women.

A case-control study in southeast China assessed 1,009 incident breast cancer cases and 1,009 age-matched healthy controls to investigate the effects of mushroom and green tea consumption. Compared with nonconsumers, multivariate-adjusted odds ratios for breast cancer were 0.36 (95% CI: 0.25-0.51) for daily intake of >=10 g fresh mushrooms and 0.53 (95% CI: 0.38-0.73) for >=4 g dried mushrooms, with significant dose-response trends (p < 0.001) in both pre- and postmenopausal women. Compared with nonconsumers of both, ORs were 0.11 (95% CI: 0.06-0.20) for high fresh mushrooms plus >=1.05 g/day dried green tea leaves, and 0.18 (95% CI: 0.11-0.29) for high dried mushrooms plus green tea (trend p < 0.001).

Shows an association, not proof of cause and effect.

Zhang M, Huang J, Xie X, et al. Int J Cancer, 2009. PMID 19048616

2006 / Narrative review of systematic reviews and clinical experiments

A review examined the biomedical effects of dietary fiber beta-glucan from sources like barley, oats, yeast, and mushrooms.

Beta-glucan is a polysaccharide fiber found in grains such as barley, oats, yeast, and mushrooms. The authors reviewed systematic reviews and clinical experiments evaluating the biomedical effects of beta-glucan, including lipid lowering, blood sugar reduction, weight reduction, immune modulation, and anticarcinogenic effects. The review aimed to identify issues and help develop future research strategies.

Kim SY, Song HJ, Lee YY, et al. J Korean Med Sci, 2006. PMID 17043406